Siu Tim Cheung

List of Publications by Year in Descending Order

82 papers	4,489 citations	34 h-index	66 g-index
94 ext. papers	4,919 ext. citations	7.2 avg, IF	4.85 L-index

#	Paper	IF	Citations
82	Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression.. *Nature Communications*, **2022**, 13, 156	17.4	4
81	Contaminated and misidentified cell lines commonly use in cancer research. *Molecular Carcinogenesis*, **2020**, 59, 573-574	5	4
80	Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 10705-10713	5.6	2
79	Clinical application of Albumin-Bilirubin (ALBI) score: The current status. *Journal of the Royal College of Surgeons of Edinburgh*, **2020**, 18, 178-186	2.5	11
78	The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. *Cancer Letters*, **2019**, 457, 98-109	9.9	17
77	STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. *Cancers*, **2019**, 11,	6.6	40
76	C-terminal truncated HBx protein activates caveolin-1/LRP6/β-catenin/FRMD5 axis in promoting hepatocarcinogenesis. *Cancer Letters*, **2019**, 444, 60-69	9.9	16
75	A Brief Overview of Progranulin in Health and Disease. *Methods in Molecular Biology*, **2018**, 1806, 3-15	1.4	29
74	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. *Translational Gastroenterology and Hepatology*, **2018**, 3, 89	5.2	20
73	Establishment and characterization of new tumor xenografts and cancer cell lines from EBV-positive nasopharyngeal carcinoma. *Nature Communications*, **2018**, 9, 4663	17.4	63
72	Granulin epithelin precursor promotes colorectal carcinogenesis by activating MARK/ERK pathway. *Journal of Translational Medicine*, **2018**, 16, 150	8.5	9
71	Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma. *Hepatobiliary and Pancreatic Diseases International*, **2018**, 17, 524-530	2.1	3
70	Mouse Monoclonal Antibodies Against Progranulin (PGRN/GEP) as Therapeutics in Preclinical Cancer Models. *Methods in Molecular Biology*, **2018**, 1806, 131-144	1.4	1
69	Methods to Analyze the Role of Progranulin (PGRN/GEP) on Cancer Stem Cell Features. *Methods in Molecular Biology*, **2018**, 1806, 145-153	1.4	1
68	Granulin-epithelin precursor interacts with 78-kDa glucose-regulated protein in hepatocellular carcinoma. *BMC Cancer*, **2017**, 17, 409	4.8	6
67	Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. *Hepatology*, **2016**, 64, 2062-2076	11.2	122
66	Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line. *Cancer Cell International*, **2016**, 16, 41	6.4	12

65	Hepatic cancer stem cell marker granulin-epithelin precursor and Ecatenin expression associate with recurrence in hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 21644-57	3.3	21
64	Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma. *PLoS ONE*, **2016**, 11, e0156833	3.7	23
63	Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. *Nature Genetics*, **2016**, 48, 747-57	36.3	187
62	Copy number gain of granulin-epithelin precursor (GEP) at chromosome 17q21 associates with overexpression in human liver cancer. *BMC Cancer*, **2015**, 15, 264	4.8	4
61	Restoration of natural killer activity in hepatocellular carcinoma by treatment with antibody against granulin-epithelin precursor. *OncoImmunology*, **2015**, 4, e1016706	7.2	13
60	Glioma Association and Balancing Selection of ZFPM2. *PLoS ONE*, **2015**, 10, e0133003	3.7	5
59	Establishment and characterization of a novel primary hepatocellular carcinoma cell line with metastatic ability in vivo. *Cancer Cell International*, **2014**, 14, 103	6.4	22
58	Granulin-epithelin precursor interacts with heparan sulfate on liver cancer cells. *Carcinogenesis*, **2014**, 35, 2485-94	4.6	13
57	MicroRNA-494 within an oncogenic microRNA megacluster regulates G1/S transition in liver tumorigenesis through suppression of mutated in colorectal cancer. *Hepatology*, **2014**, 59, 202-15	11.2	97
56	Granulin-epithelin precursor renders hepatocellular carcinoma cells resistant to natural killer cytotoxicity. *Cancer Immunology Research*, **2014**, 2, 1209-19	12.5	28
55	Antibody against granulin-epithelin precursor sensitizes hepatocellular carcinoma to chemotherapeutic agents. *Molecular Cancer Therapeutics*, **2014**, 13, 3001-12	6.1	23
54	Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. *Chinese Journal of Cancer*, **2014**, 33, 529-38		18
53	Complete genomic sequence of Epstein-Barr virus in nasopharyngeal carcinoma cell line C666-1. *Infectious Agents and Cancer*, **2013**, 8, 29	3.5	32
52	Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. *Carcinogenesis*, **2013**, 34, 1001-5	4.6	18
51	Identification and characterization of tropomyosin 3 associated with granulin-epithelin precursor in human hepatocellular carcinoma. *PLoS ONE*, **2012**, 7, e40324	3.7	20
50	CD44+ cancer stem-like cells in EBV-associated nasopharyngeal carcinoma. *PLoS ONE*, **2012**, 7, e52426	3.7	60
49	Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. *Nature Genetics*, **2011**, 44, 62-6	36.3	141
48	Granulin-epithelin precursor and ATP-dependent binding cassette (ABC)B5 regulate liver cancer cell chemoresistance. *Gastroenterology*, **2011**, 140, 344-55	13.3	114

47	Granulin-epithelin precursor is an oncofetal protein defining hepatic cancer stem cells. *PLoS ONE*, **2011**, 6, e28246	3.7	42
46	Bmi1 functions as an oncogene independent of Ink4A/Arf repression in hepatic carcinogenesis. *Molecular Cancer Research*, **2009**, 7, 1937-45	6.6	55
45	New tools for functional genomic analysis. *Drug Discovery Today*, **2009**, 14, 754-60	8.8	26
44	Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma. *Transplantation*, **2008**, 85, 81-7	1.8	28
43	Granulin-epithelin precursor as a therapeutic target for hepatocellular carcinoma. *Hepatology*, **2008** , 47, 1524-32	11.2	90
42	Atypical localization of membrane type 1-matrix metalloproteinase in the nucleus is associated with aggressive features of hepatocellular carcinoma. *Molecular Carcinogenesis*, **2007**, 46, 225-30	5	51
41	Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. *Modern Pathology*, **2007**, 20, 76-83	9.8	91
40	Down-regulation of retinol binding protein 5 is associated with aggressive tumor features in hepatocellular carcinoma. *Journal of Cancer Research and Clinical Oncology*, **2007**, 133, 929-36	4.9	7
39	Distinct pathways of genomic progression to benign and malignant tumors of the liver. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 14771-6	11.5	165
38	Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. *Biomarkers in Medicine*, **2007**, 1, 273-84	2.3	17
37	Inhibition of hepatocellular carcinoma invasion by suppression of claudin-10 in HLE cells. *Molecular Cancer Therapeutics*, **2007**, 6, 2858-67	6.1	38
36	Increased expression of glycosyl-phosphatidylinositol anchor attachment protein 1 (GPAA1) is associated with gene amplification in hepatocellular carcinoma. *International Journal of Cancer*, **2006**, 119, 1330-7	7.5	32
35	Hedgehog signaling in human hepatocellular carcinoma. *Cancer Biology and Therapy*, **2006**, 5, 111-7	4.6	87
34	Liver intestine-cadherin (CDH17) haplotype is associated with increased risk of hepatocellular carcinoma. *Clinical Cancer Research*, **2006**, 12, 5248-52	12.9	31
33	Preoperative plasma transcript AA454543 level is an independent prognostic factor for hepatocellular carcinoma after partial hepatectomy. *Neoplasia*, **2006**, 8, 696-701	6.4	8
32	GEP associates with wild-type p53 in hepatocellular carcinoma. *Oncology Reports*, **2006**, 15, 1507	3.5	1
31	Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. *Annals of Surgery*, **2006**, 244, 194-203	7.8	184
30	SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. *Journal of Pathology*, **2006**, 210, 459-68	9.4	65

29	GEP associates with wild-type p53 in hepatocellular carcinoma. *Oncology Reports*, **2006**, 15, 1507-11	3.5	13
28	Transcript AA454543 is a novel prognostic marker for hepatocellular carcinoma after curative partial hepatectomy. *Neoplasia*, **2005**, 7, 91-8	6.4	9
27	Cyclins and CDKs in Liver Diseases **2005**, 325-331		
26	An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. *Oncogene*, **2005**, 24, 3737-47	9.2	107
25	Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma. *Carcinogenesis*, **2005**, 26, 2050-7	4.6	113
24	Mechanism of metastasis by membrane type 1-matrix metalloproteinase in hepatocellular carcinoma. *World Journal of Gastroenterology*, **2005**, 11, 6269-76	5.6	18
23	Claudin-10 expression level is associated with recurrence of primary hepatocellular carcinoma. *Clinical Cancer Research*, **2005**, 11, 551-6	12.9	80
22	Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. *Clinical Cancer Research*, **2004**, 10, 7629-36	12.9	104
21	Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. *Clinical Cancer Research*, **2004**, 10, 4150-7	12.9	86
20	Novel endothelial cell markers in hepatocellular carcinoma. *Modern Pathology*, **2004**, 17, 1198-210	9.8	69
19	Decreased expression of cytochrome P450 2E1 is associated with poor prognosis of hepatocellular carcinoma. *International Journal of Cancer*, **2004**, 111, 494-500	7.5	27
18	De novo sarcoma of donor origin in a liver allograft determined by microsatellite analysis: a short report. *Liver Transplantation*, **2004**, 10, 320-3	4.5	5
17	Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. *Liver Transplantation*, **2004**, 10, 557-63	4.5	26
16	Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. *Hepatology*, **2003**, 37, 36-43	11.2	59
15	Liver as an ideal target for gene therapy: expression of CTLA4Ig by retroviral gene transfer. *Journal of Gastroenterology and Hepatology (Australia)*, **2002**, 17, 1008-14	4	24
14	Gene expression patterns in human liver cancers. *Molecular Biology of the Cell*, **2002**, 13, 1929-39	3.5	680
13	Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. *Cancer Research*, **2002**, 62, 4711-21	10.1	74
12	Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. *Annals of Surgery*, **2001**, 233, 276-81	7.8	110

11	Novel intertypic recombinants of epstein-barr virus in the chinese population. *Journal of Virology*, **2000**, 74, 1544-8	6.6	55
10	CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells. *Journal of Immunology*, **2000**, 165, 573-82	5.3	96
9	Evaluation of quantitative PCR and branched-chain DNA assay for detection of hepatitis B virus DNA in sera from hepatocellular carcinoma and liver transplant patients. *Journal of Clinical Microbiology*, **2000**, 38, 1977-80	9.7	9
8	Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology (Australia)*, **2000**, 15 Suppl, E181-6	4	18
7	Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. *British Journal of Cancer*, **1999**, 81, 1122-6	8.7	40
6	Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. *International Journal of Cancer*, **1999**, 83, 121-6	7.5	304
5	Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus **1999**, 83, 121		2
4	Characterization of a new EBV-associated nasopharyngeal carcinoma cell line. *Cancer Genetics and Cytogenetics*, **1998**, 101, 83-8		34
3	Specific latent membrane protein 1 gene sequences in type 1 and type 2 Epstein-Barr virus from nasopharyngeal carcinoma in Hong Kong. *International Journal of Cancer*, **1998**, 76, 399-406	7.5	56
2	Prevalence of LMP1 deletion variant of Epstein-Barr virus in nasopharyngeal carcinoma and gastric tumors in Hong Kong. *International Journal of Cancer*, **1996**, 66, 711-2	7.5	52
1	Prevalence of LMP1 deletion variant of Epstein-Barr virus in nasopharyngeal carcinoma and gastric tumors in Hong Kong **1996**, 66, 711		1